Skip to main content

APG-2575 Study of Safety, Tolerability ,PK / PD in Patients With Hematologic Malignancies

Trial Status: Active

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Inclusion Criteria

  • Inclusion Criteria: 1. Age ≥18 years old. 2. Histologically confirmed diagnosis of either one of the B-cell hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM) and acute myeloid leukemia 3. Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit. In addition, a. AML Patients will be eligible if they have failed standard induction regimen, are not considered candidate for further chemotherapy or stem cell transplantation or have primary refractory AML. 4. Life expectancy ≥ 3 months. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation ; 0-2 in dose expansion. 6. QTc interval ≤450ms in males, and ≤470ms in females. 7. Adequate bone marrow function independent of growth factor: 8. Absolute neutrophil count (ANC) ≥1.0 X 109/L. 9. Hemoglobin ≥ 8.0 g/dL. 10. Platelets count ≥ 30 X 109/L (entry platelet count must be independent of transfusion within 7 days of first dose). 11. Adequate renal and liver function as indicated by: Exclusion Criteria: Patients who meet any of the following exclusion criteria are not to be enrolled in this study: 1. Prior history of allogeneic cell transplant. 2. Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia. 3. Received chemotherapy within 14 days (42 days for nitrosoureas or mitomycin C) prior to entering the study. 4. Received biologic (< 28 days), small molecule targeted therapies (< 5 half-life) or other anti-cancer therapy within 21 days of study entry. 5. Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry. 6. Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator. 7. Has known active central nervous system (CNS) involvement. 8. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy. 9. Concurrent treatment with an investigational agent, 14 days for small molecular agents and/or 28 days for biologics treatment prior to the first dose of therapy. 10. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry. 11. Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry. 12. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation. 13. Active infection requiring systemic antibiotic/ antifungal medication, known clinically active hepatitis B or C infection, or on antiretroviral therapy for HIV disease.


Mayo Clinic in Arizona
Status: ACTIVE


Mayo Clinic in Florida
Status: ACTIVE


Mayo Clinic in Rochester
Status: ACTIVE

North Carolina

Duke University Medical Center
Status: ACTIVE


M D Anderson Cancer Center
Status: ACTIVE

APG-2575 will be administered orally, once daily for consecutive 4 weeks as one cycles.

Initially, the start dose is 20mg. Single patient cohorts will be evaluated, the dose of

APG-2575 will be increased in subsequent cohorts, to 50 mg, 100 mg, 200 mg, 400 mg, 600mg and

800mg accordingly. If there is any one of the following event is observed, a DLT, two drug

related Grade 2 toxicities or one drug related ≥ Grade 3 toxicity, or laboratory or clinical

TLS, or suspected hypersensitivity reaction occur in Cycle 1, or dose level of 400 mg is

reached, the dose escalation will convert to the standard 3+3 design, If ≥ 2/6 patients

develop DLT at any dose level dose escalation will cease and the dose level immediately below

will be expanded to 6 patients. If ≤ 1/6 patients develop a DLT at the highest dose reached

this will be declared the MTD. After the MTD is defined, a maximum of 20 patients will be

treated at that dose level.

Trial Phase Phase O

Trial Type Treatment

Lead Organization
Ascentage Pharma Group Inc.

  • Primary ID APG2575-001
  • Secondary IDs NCI-2018-02408, APG-2575
  • ID NCT03537482